title: Malignant thymoma: current status of classification and multimodality treatment.
abstract: Classification, understanding of the pathophysiology, and treatment options of thymoma have changed during recent years. It is hoped that novel strategies will lead to a survival benefit in these patients. It has become clear that patients with thymoma are best treated with multimodality therapy. In this review, a pathologist, an immunologist, a surgeon, a radiotherapist, a pneumologist, and oncologists discuss the current status of classification and strategies for the treatment of patients with thymoma.
authors.affiliation: Medizinische Klinik und Poliklinik I, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Str. 25, 53105, Bonn, Germany. picasso@uni-bonn.de.
authors.forename: I G H
authors.initials: IGH
authors.lastname: Schmidt-Wolf
authors.affiliation: Medizinische Klinik und Poliklinik I, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Str. 25, 53105, Bonn, Germany.
authors.forename: J K
authors.initials: JK
authors.lastname: Rockstroh
authors.affiliation: Klinik und Poliklinik für Radiologie, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Schüller
authors.affiliation: Klinik und Poliklinik für Chirurgie, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Hirner
authors.affiliation: Medizinische Klinik und Poliklinik II, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Grohe
authors.affiliation: Pathologisches Institut der Universität Würzburg, Würzburg, Germany.
authors.forename: H K
authors.initials: HK
authors.lastname: Müller-Hermelink
authors.affiliation: Charité, Campus Virchow Klinikum, Klinik für Innere Medizin mit Schwerpunkt Hämatologie-Onkologie, Humboldt-Universität zu Berlin, Berlin, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Huhn
mesh_terms: D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D009367:Neoplasm Staging; D015996:Survival Rate; D013945:Thymoma / Q000145:classification* / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome